MyMD CSO Dr. Adam Kaplin resigns effective immediately; no disagreement cited

Q/C TECHNOLOGIES, INC.

Dr. Adam Kaplin resigned as Chief Scientific Officer on April 15, 2024, effective immediately.
Resignation not due to any disagreement with the company, management, or board.
No replacement named; company's future CSO plans are undisclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Adam Kaplin

Chief Scientific Officer

QCLS · Q/C TECHNOLOGIES, INC.

Effective: 2024-04-15
Filed: April 18, 2024, 7:59 PM ET

On April 15, 2024, Adam Kaplin, M.D., Ph.D., who served as Chief Scientific Officer of MyMD Pharmaceuticals, Inc. (the “Company”), tendered his resignation from his role as an officer of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Adam Kaplin resigned as Chief Scientific Officer at Q/C TECHNOLOGIES, INC..

Action: resigned
Role: Chief Scientific Officer

Exact text from the filing

On April 15, 2024, Adam Kaplin, M.D., Ph.D., who served as Chief Scientific Officer of MyMD Pharmaceuticals, Inc. (the “Company”), tendered his resignation from his role as an officer of the Company, effective immediately.

View on SEC.gov

Q/C TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-015199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.